Category: New products
-
Self-Applied Patch Shown Feasible for Vaccine Delivery
A clinical trial shows a microneedle patch device for vaccine delivery applied by participants to their own arms works as well in the skin as when administered by clinicians.
-
T-Cell Biotech Gains €17.5M in Grant, Equity Funds
A developer of engineered immune cells to treat cancer and immune deficiencies is raising €17.5 million ($US 19.1 million) in equity and grant funding from an EU agency.
-
Chewable Covid-19 Drug Reduces Viral Load, Symptoms
Clinical trial results show an experimental drug given as a chewable tablet reduces viral load and symptoms in people with mild to moderate Covid-19 disease.
-
$50M Challenge Seeks Quantum Life Science Applications
A new challenge competition seeks life science research applications for quantum computing that take advantage of the technology’s unique computational properties.
-
Industry, Academic Labs Detailing ALS Treatment Actions
Researchers from a developer of neurodegenerative disease therapies and university medical center are investigating the precise workings of a promising ALS treatment.
-
Infographic – Six Generative A.I. Applications
As our infographic indicates, generative A.I. can be applied in a range of industries, particularly in design and discovery functions.
-
Screening Device Company Kicks-Off Type 1 Diabetes Network
A developer of a blood-testing device that screens for kidney disease risks is the first company to join a network to advance new technology for type 1 diabetes.
-
Start-Up Licenses Protein Therapy Tech, Raises $50M
A new company making antibodies that degrade disease-causing proteins on and outside cell surfaces is raising $50 million in its first venture funding round.
-
Trial to Test Low-Dose Psilocybin for Mental Distress
A developer of mental health therapies from psychedelic compounds says it received FDA clearance for a clinical trial testing low doses of psilocybin.
-
HPV Vaccine Generates Immune Responses in Trial
Early results from a clinical trial show a vaccine for the human papillomavirus is safe and invokes immune responses in women with low-grade cervical lesions.